Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Payables: 2011-2024

Historic Payables for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $3.3 million.

  • Capricor Therapeutics' Payables fell 58.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 36.23%. This contributed to the annual value of $3.3 million for FY2024, which is 47.46% down from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Payables is $3.3 million, which was down 47.46% from $6.3 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Payables peaked at $6.3 million during FY2023, and registered a low of $3.0 million during FY2020.
  • Over the past 3 years, Capricor Therapeutics' median Payables value was $4.8 million (recorded in 2022), while the average stood at $4.8 million.
  • Its Payables has fluctuated over the past 5 years, first spiked by 229.88% in 2020, then slumped by 47.46% in 2024.
  • Capricor Therapeutics' Payables (Yearly) stood at $3.0 million in 2020, then climbed by 5.20% to $3.1 million in 2021, then soared by 55.14% to $4.8 million in 2022, then climbed by 29.28% to $6.3 million in 2023, then tumbled by 47.46% to $3.3 million in 2024.